Vaxart Inc (VXRT) concluded trading on Wednesday at a closing price of $0.50, with 93.69 million shares of worth about $46.84 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -19.74% during that period and on June 11, 2025 the price saw a gain of about 28.30%. Currently the company’s common shares owned by public are about 228.22M shares, out of which, 222.22M shares are available for trading.
Stock saw a price change of 24.78% in past 5 days and over the past one month there was a price change of 24.47%. Year-to-date (YTD), VXRT shares are showing a performance of -23.86% which decreased to -34.64% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.28 but also hit the highest price of $1.07 during that period. The average intraday trading volume for Vaxart Inc shares is 2.05 million. The stock is currently trading 13.21% above its 20-day simple moving average (SMA20), while that difference is up 25.08% for SMA50 and it goes to -19.94% lower than SMA200.
Vaxart Inc (NASDAQ: VXRT) currently have 228.22M outstanding shares and institutions hold larger chunk of about 18.85% of that.
The stock has a current market capitalization of $115.09M and its 3Y-monthly beta is at 1.14. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 0.64 while making debt-to-equity ratio of 0.45. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VXRT, volatility over the week remained 12.72% while standing at 8.13% over the month.
Stock’s fiscal year EPS is expected to rise by 15.15% while it is estimated to decrease by -35.71% in next year. EPS is likely to shrink at an annualized rate of -6.35% for next 5-years, compared to annual growth of 17.46% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on August 15, 2024 offering an Outperform rating for the stock and assigned a target price of $4 to it. Coverage by Jefferies stated Vaxart Inc (VXRT) stock as a Buy in their note to investors on December 29, 2021, suggesting a price target of $12 for the stock. On November 02, 2021, Cantor Fitzgerald Initiated their recommendations, while on June 29, 2021, B. Riley Securities Downgrade their ratings for the stock with a price target of $9. Stock get a Buy rating from Jefferies on June 24, 2021.
